| Epoetin ($5.4 billion/$1 billion) 2007 |
2007 |
Not Available (2003) |
$610 million;
$95 million[@129271; @129272] |
2004, 2006, 2007, 2008, 2010, 2011 |
None |
| Darbepoetin ($4.1 billion/$1.7 billion) 2007 |
2007 |
Not Available (2003) |
$610 million;
$95 million[@129271; @129272] |
2004, 2006, 2007, 2008, 2010, 2011 |
2012: Amgen plead guilty to one criminal count of illegally introducing a misbranded drug and providing false information (for darbepoetin) into commerce. ($150 million fine).[@129271] |
Rosiglitazone
($3 billion/$0.2 billion) 2007 |
1999 |
47,000 (2007)[@129285] |
2011 GlaxoSmithKline set aside $3.4 billion to pay patients to settle individual lawsuits for injury[@129273] |
2007, 2010, 2013 |
2012: GSK pled guilty to federal and charges of failing to report clinical data. ($3 billion in Federal penalties and $319 million for state penalties).[@129273] |
| Rofecoxib ($2.5 billion/ 2004, withdrawn in 2004) |
2001, 2001, 2001 (three persons) |
88,000- 140,000 (2005) |
Merck paid $4.85 billion (to patients for injuries).[@129185] |
2004,2005 |
2011: Merck pled guilty to criminal misdemeanor of illegal promotional activity ($321 million fine).[@129300] |
| Fenfluramine-phentermine ($0.3 billion 1996/ drug withdrawn 1997) |
1996 (two cli-nicians) |
300,000 (1996) |
Wyeth paid $22 billion (to patients for injuries)[@129284] |
2000 |
None |
| Benfluorex ($500 million 2008/drug withdrawn in 2009) |
2007 |
2,000 deaths; 6,500 injured patients (2010) |
Servier paid $146 million- patients
$3.2 million and $0.5 million to the ANSM, the French pharmaceutical regulatory agency[@129214] |
2011, 2021 (French courts) |
2021: Manslaughter and criminal deceit- Servier and former Servier executive (four-year suspended sentence). ($3.3 million fine against Servier)[@129299] |
| Gadodiamide ($0.54 billion/ $0.2 billion 2020) |
2007 |
Not known (2006) |
General Electric $500 million (to patients) (reportedly) |
2009 |
None |
| Atrazine (still sold) |
2002 |
Not known (2002) |
Syngenta paid $105 million (to 105 counties to settle class action lawsuit related to public water contamination)[@129282] |
2012, 2020 |
None |
| Ivermectin (no known sales numbers) |
2004 |
5,552 dogs with toxicity (2004) |
No fines were paid by Fort Dodge Animal Health |
2004,2005 |
None |
| Paroxetine - 2009 use returned to 2004 levels |
2004 |
Many cases (1991) |
GlaxoSmithKline pain patients $3 billion[@129301] |
2004 |
2012: GlaxoSmithKline pled guilty to a 3-count criminal information charge, including one count of misbranding paroxetine. (Criminal fine of $956 million)[@129301] |
| Risedronate (risedronate) |
2002 |
Not known |
Not applicable |
2005- UK |
None |
| Phenyl-propanolamine (drug withdrawn) ($200 million 1999/$0 in 2000) |
2000 |
Not known |
Not available. Cases were settled privately. |
2000 |
None |
| Articular surface hip replacements (US recall-2010) |
2007 |
8,000 persons |
$4 billion to patients for faulty hip prostheses[@129280] |
2011 (Australia); 2012 (FDA) |
None |
| Synthroid |
2004 |
None reported |
$42 million (states) $98 million (class action settlement)[@129281; @129282] |
None |
None |
| Valdecoxib |
2004 |
1,100 persons (2005) |
Pharmacia paid $745 million (personal injury claims settlement). Also paid $1 billion in civil settlement for False Claims Act violation.[@129295; @129302] |
2005 |
2009: Pharmacia pled guilty to a federal violation of misbranding valdecoxib with the intent to defraud or mislead. Paid $1.3 billion in criminal fine.[@129302] |